Your Article Summary
See Latest ArticlesPotential Clinical and Economic Outcomes of CYP2C9 and VKORC1 Genotype-Guided Dosing in Patients Starting Warfarin Therapy
Clinical Pharmacology & Therapeutics, 07/02/09
You JHS et al. - Genotype-guided dosing for warfarin therapy does not appear to be cost-effective, with the potential ICER per QALY being >$50,000. Lowering the genotyping cost, improving effectiveness of INR control of the genotype-guided dosing algorithm, and applying the algorithm in practice sites with high out-of-range INRs would improve the cost-effectiveness of the dosing algorithm.
Today in Dosing...keeping you current
Receive free subspecialty "5-minute updates" via email
Congenital abnormalities in children of 43 pregnant women who attempted suicide with large doses of nitrazepam
Pharmacoepidemiology and Drug Safety, 12/09/09
Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers
British Journal of Clinical Pharmacology, 12/09/09
Allos Therapeutics' FOLOTYN Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-Cell Lymphoma
Allos Therapeutics, 12/09/09
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
The Impact of Disposables on Project Economics in a New Antibody Plant
BioPharm, 12/09/09
Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin
American Journal of Health-System Pharmacy, 12/08/09
Costs and benefits of dropout schedules of test-restudy practice: Implications for student learning
Applied Cognitive Psychology, 12/07/09